HLS Therapeutics Growth, Revenue, Number of Employees and Funding
Estimated Revenue & Financials
- HLS Therapeutics's estimated revenue is currently $9.8M per year.
- HLS Therapeutics received $125.0M in venture funding in September 2018.
- HLS Therapeutics's estimated revenue per employee is $189404
- HLS Therapeutics has 52 Employees.
- HLS Therapeutics grew their employee count by 33% last year.
- HLS Therapeutics currently has 1 job openings.
|Greg Gubitz||Chief Executive Officer|
|Gilbert Godin||President and Chief Operating Officer|
|Tim Hendrickson||Chief Financial Officer|
|sanjiv Sharma||Chief Commercial Officer|
|Jason Gross||VP Scientific Affairs|
|Carmel Daughtery||VP Integration Management|
|Jeff Webb||Sr. Director of Marketing and Sales, Neuroscience|
What Is HLS Therapeutics?
The Heritage of Life Sciences Products HLS Therapeutics is about maintaining the heritage of life science products. We are dedicated to keeping trusted branded drugs on the market. HLS provides access to medications critical to Health Care Providers, patients and their caregivers with the high-quality brand names they trust. Who We Are HLS Therapeutics Inc. is a specialty pharmaceutical company dedicating itself to acquiring and distributing commercial stage mature, or legacy, branded pharmaceutical drugs for the North American markets. Our management team is comprised of seasoned pharmaceutical executives with a strong track record of success. Building on the expertise of our founders, HLS is focused on treatment products for the central nervous system, soon to be followed by specialty products in other therapeutic areas. HLS Therapeutics focuses on the North American market and has operational locations in Toronto (Etobicoke, Ontario), and Philadelphia (Rosemont, Pennsylvania), We source our products from the drug's originator or from best-in-class manufacturing partners, ensuring our brands are manufactured with the highest standards of quality and in compliance with FDA and Health Canada's regulations. Our Goal/Our Mission HLS is dedicated to the stewardship of branded pharmaceuticals through their life cycle during and post exclusivity, providing access to treatments critical to Health Care Providers, patients and their caregivers with the brand names they trust.keywords:N/A
Number of Employees
Employee Growth %
|Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|Fresenius Kabi ...||$21.7M||116||22%|
|Dalton Pharma S...||$25.1M||134||5%|
HLS Therapeutics News
HLS Therapeutics Inc. (TSE:HLS) shareholders might be concerned after seeing the share price drop 18% in the last month. But looking back ...
HLS Therapeutics has only been paying a dividend for a year or so, so investors might be curious about its 1.4% yield.” Before you buy any ...
HLS Therapeutics Inc. (TSX:HLS) has a current EV or Enterprise Value of 457566. The EV displays how the market assigns value to a firm as a ...
HLS Therapeutics Funding
|2018-09-13||$125.0M||Undisclosed||Silicon Valley Bank||Article|